Patrick Neven, MD, Universitair Ziekenhuis Leuven, Leuven, Belgium, provides an overview of the Phase I EMBER-2 (NCT04647487) window-of-opportunity study investigating the biological effects of imulnestrant administered two weeks prior to surgery for patients with estrogen receptor positive (ER+), HER2-negative (HER2-) early stage (stage I-III) breast cancer. The primary outcome was change from baseline in ER expression and secondary outcomes included change from baseline in progesterone receptor (PR) expression and change in baseline in Ki-67 index. ER expression was shown to be reduced, as well as PR and Ki-67 index. Complete cell cycle arrest was also observed. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.